We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS’ Opdivo Fails as PD-L1 Monotherapy in Untreated NSCLC, Giving Edge to Merck
BMS’ Opdivo Fails as PD-L1 Monotherapy in Untreated NSCLC, Giving Edge to Merck
Bristol-Myers Squibb presented results from several clinical trials of its PD-L1 immunotherapy, Opdivo, including more detailed data from a Phase III trial that failed to show benefits as a first-line monotherapy in advanced non-small cell lung cancer.